Helix News and Research

RSS

Rapid detection of transiently folded single-molecule structures from 'intrinsically disordered proteins'

A team of scientists from The Scripps Research Institute and the University of California, San Diego (UCSD) have developed a novel technique to observe previously unknown details of how folded structures are formed from an intrinsically disordered protein. The insights could help scientists to better understand the mechanism of plaque formation in neurodegenerative disorders such as Parkinson's and Alzheimer's diseases.

9 Feb 2011

Novel technique could speed up the development of peptide-based drugs against cancer

Researchers at the University at Buffalo have devised two new ways of "stapling" peptide helices to prevent these medically important molecules from losing their shape and degrading in the presence of enzymes.

9 Feb 2011

Scientists develop novel technique to detect disordered protein folding

A team of scientists from The Scripps Research Institute and the University of California, San Diego have developed a novel technique to observe previously unknown details of how folded structures are formed from an intrinsically disordered protein.

9 Feb 2011

Helix Medical to invest over $4M for new manufacturing facility in Costa Rica

Helix Medical, LLC, a global manufacturer for the medical device and healthcare industries, will soon begin construction on a new medical manufacturing facility in Costa Rica. Helix Medical signed a leasing agreement in The Coyol Free Trade Zone and Business Park in Alajuela, Costa Rica, just outside of San Jose. The company will invest more than $4M in the new plant that will soon employ more than 100 people.

7 Feb 2011

Golden Helix releases new Sequence Analysis Module for SNP & Variation Suite

Golden Helix, Inc. today announced the release of a new Sequence Analysis Module for its SNP & Variation Suite software. The new module introduces innovative tertiary analysis methods for next-generation DNA sequencing studies.

27 Jan 2011

Golden Helix accelerates copy number variation detection methodology

Golden Helix, Inc., today announced the incorporation of technologies that will greatly accelerate genetic research. By enabling the company's SNP & Variation Suite software to run on off-the-shelf video graphics cards, or GPUs, operations that took hours or days can now be completed in a fraction of the time - and without the need for expensive compute clusters or resorting to cloud-based computing. This novel ability will dramatically accelerate many forms of computationally expensive genetic analyses, including that of next generation sequencing data.

27 Oct 2010

UCSF professor receives National Medal of Science

UCSF Nobel laureate Stanley B. Prusiner, MD, UCSF professor of neurology and director of the Institute for Neurodegenerative Diseases, today (Oct. 15, 2010) was named to receive the National Medal of Science, the nation's highest honor for science and technology.

18 Oct 2010

Sirius collaborates with Golden Helix to advance diagnostic pipeline

Sirius Genomics, a developer of companion diagnostics, and Golden Helix, a global leader in genetic analysis solutions, announced today a collaboration under which Golden Helix will apply its expertise and technologies in SNP and copy number variant analysis and predictive modeling to advance development of Sirius' diagnostic pipeline.

13 Oct 2010

Helix completes GLP toxicology study milestone in L-DOS47 development program

Helix BioPharma Corp. today announced that it has completed its definitive GLP, rodent and primate, repeat-dose toxicology studies with L-DOS47. These studies demonstrated a good safety profile in an expanded number of rodent and primate test animals, building upon Helix's positive findings from its preliminary non-GLP toxicology studies.

12 Oct 2010

Researchers discover new mechanism of DNA repair process

Tucked within its double-helix structure, DNA contains the chemical blueprint that guides all the processes that take place within the cell and are essential for life. Therefore, repairing damage and maintaining the integrity of its DNA is one of the cell's highest priorities.

4 Oct 2010

Golden Helix refactors HSPH's software for studying disease heritability in families

Today, Golden Helix, Inc., a global leader in genetic analysis solutions, announced a collaboration with Harvard School of Public Health (HSPH) under which Golden Helix is refactoring PBAT, HSPH's software for studying disease heritability in families.

23 Sep 2010

Cellectis bioresearch, Helix Biocon collaborate to promote cGPS service in India

Cellectis bioresearch, the specialist in genome customization and subsidiary of Cellectis and Helix BioService & Consultants Pvt Ltd (Helix Biocon), today announced that they will join forces for the promotion of Cellectis bioresearch's meganuclease-based products and services in India.

20 Sep 2010

Helix BioPharma receives authorization to list shares on NYSE Amex stock exchange

Helix BioPharma Corp. today announced that it has been authorized to list its shares of common stock on the NYSE Amex stock exchange. The Company expects that shares of its common stock will begin trading on the NYSE Amex on September 15, 2010, under the trading symbol "HBP."

15 Sep 2010

Researchers unveil protection mechanism of telomeres from DNA repair

In the latest issue of the journal Nature, Miguel Godinho Ferreira, Principal Investigator at the Instituto Gulbenkian de Ciência (IGC) in Portugal, lead a team of researchers to shed light on a paradox that has puzzled biologists since the discovery of telomeres, the protective tips of chromosomes: while broken chromosome ends generated by DNA damage (such as radiation or cigarette smoke) are quickly joined together, telomeres are never tied to each other, thus allowing for the correct segregation of the genetic material into all cells in our body.

9 Sep 2010

Researchers develop tiny color-changing sensor molecules

A new approach to building an "artificial nose" using fluorescent compounds and DNA could accelerate the use of sniffing sensors into the realm of mass production and widespread use, say Stanford chemists. If their method lives up to its promise, it could one day detect everything from incipiently souring milk to high explosives.

21 Aug 2010

Helix BioPharma closes private placement of 4,530,000 units

Helix BioPharma Corp. today announced that it has closed a private placement of 4,530,000 units at $2.43 per unit.

7 Aug 2010

Helix BioMedix second-quarter revenue increases 139% to $330,000

Helix BioMedix, Inc., a developer of bioactive peptides, today announced financial results for the company's second quarter 2010 ended June 30, 2010.

7 Aug 2010

Genetics research team discovers new recurrent translocations

A genetics research team based at The Children's Hospital of Philadelphia continues to discover recurrent translocations—places in which two chromosomes exchange pieces of themselves. As many as 1 in 600 persons carry balanced chromosome translocations, which involve no loss or gain of DNA. Most such people appear healthy, but may have a child with abnormal chromosome composition and disabilities resulting from disrupted, extra or missing copies of genes.

30 Jul 2010

Scientists discover repair mechanism of photolyase in sun damaged DNA

Researchers have long known that humans lack a key enzyme one possessed by most of the animal kingdom and even plants that reverses severe sun damage.For the first time, researchers have witnessed how this enzyme works at the atomic level to repair sun-damaged DNA.The discovery holds promise for future sunburn remedies and skin cancer prevention.

26 Jul 2010

Genelex, Helix announce strategic alliance to increase availability of new DNA Drug Sensitivity Tests

Genelex and Helix have announced a personalized prescribing strategic alliance to increase the availability of important new DNA Drug Sensitivity Tests such as Plavitest and Tamoxitest. These tests and the GeneMedRx medication management software can save lives and healthcare dollars by allowing doctors to personalize their prescribing practices in order to prevent adverse medication outcomes, including treatment failures and dangerous side effects.

15 Jul 2010